Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin-Ji Yang

Showing results (1-10 of 176) with videos related to

Pageof 18
Sort By:
Chinese Journal of Cancer|July 12, 2015
Insight into early-phase trials for lung cancer in the United StatesJin-Ji Yang, Yi-Long Wu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?Tony Mok, Jin-Ji Yang, Kwok-Chi Lam
Clinical Lung Cancer|November 4, 2022
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS TrialAnna Li, Hua-Jun Chen, Jin-Ji Yang
Cancer Treatment Reviews|May 19, 2018
Toward innovative combinational immunotherapy: A systems biology perspectiveXue-Tao Li, Jin-Ji Yang, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2014
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trialsNing Zhao, Xu-Chao Zhang, Hong-Hong Yan, et al.
International Journal of Clinical Oncology|October 7, 2019
Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastasesZhen Wang, Jin-Ji Yang, Hai-Yan Tu, et al.
Clinical Case Reports|May 27, 2024
Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief reportJiao Yang, Jie Huang, Gongjun Yuan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 7, 2015
Do-not-resuscitate orders among advanced-stage Chinese lung cancer patients who died in hospitalZhen Wang, Yang-Si Li, Ning Zhao, et al.
Therapeutic Advances in Medical Oncology|July 29, 2025
Advances in immuno-based and targeted therapies in extensive-stage small cell lung cancerXiao-Tong Zou, Jie Huang, Hao Sun, et al.
JTO Clinical and Research Reports|June 9, 2022
Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in <i>ALK</i>-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief ReportJie Huang, Shi-Ling Zhang, Chaozheng Zhou, et al.
Pageof 18

Showing results (1-10 of 176) with videos related to

Sort By:
Pageof 18
Chinese Journal of Cancer|July 12, 2015
Insight into early-phase trials for lung cancer in the United StatesJin-Ji Yang, Yi-Long Wu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?Tony Mok, Jin-Ji Yang, Kwok-Chi Lam
Clinical Lung Cancer|November 4, 2022
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS TrialAnna Li, Hua-Jun Chen, Jin-Ji Yang
Cancer Treatment Reviews|May 19, 2018
Toward innovative combinational immunotherapy: A systems biology perspectiveXue-Tao Li, Jin-Ji Yang, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2014
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trialsNing Zhao, Xu-Chao Zhang, Hong-Hong Yan, et al.
International Journal of Clinical Oncology|October 7, 2019
Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastasesZhen Wang, Jin-Ji Yang, Hai-Yan Tu, et al.
Clinical Case Reports|May 27, 2024
Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief reportJiao Yang, Jie Huang, Gongjun Yuan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 7, 2015
Do-not-resuscitate orders among advanced-stage Chinese lung cancer patients who died in hospitalZhen Wang, Yang-Si Li, Ning Zhao, et al.
Therapeutic Advances in Medical Oncology|July 29, 2025
Advances in immuno-based and targeted therapies in extensive-stage small cell lung cancerXiao-Tong Zou, Jie Huang, Hao Sun, et al.
JTO Clinical and Research Reports|June 9, 2022
Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in <i>ALK</i>-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief ReportJie Huang, Shi-Ling Zhang, Chaozheng Zhou, et al.
Pageof 18